Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin. It enables intravascular drug release initiated by a mild heat trigger using clinical hyperthermia devices. This results in an up to 15-fold higher local tumor drug concentrations and aims to improve clinical treatment efficacy by creating a local boost. These high local concentrations, which also reach less well perfused areas, aim to overcome drug resistance. The first clinical indication of THE001 is soft tissue sarcoma.

I founded my first own company as a 17-year-old teenager in high school. While I started my career working about a decade in corporate strategy and management (Bain & Co., ZEISS), an entrepreneurial role was something I always envisioned. For me, life sciences is a particularly rewarding industry as we develop meaningful products that may one day make this world a better place, for instance, by offering better treatment options for severe diseases. At Thermosome, we strive to improve the treatment of locally advanced tumors. With our technology, we achieve up to 15-fold higher local drug concentrations, potentially making treatments much more effective. If successful, we may one day offer a curative treatment to patients with certain locally advanced tumors. This is the vision we are all working for.